MNCs in Serbia move for "transparency"
Multinational pharmaceutical companies operating in Serbia have signed a letter of intent on the formation of an association to promote transparency in the industry, as well as to encourage improvement of Serb people's health and citizens' quality of life.
Th letter was signed by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen Cilag, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi-Aventis and Schering-Plough. The members of the future association said that they were ready to cooperate with state institutions and non-government organizations in an effort to improve public health in Serbia.
They also stated that they wanted to maintain the highest level of transparency possible in relations between state institutions and representatives of the pharmaceutical industry, as well as to establish a code of business ethics for all pharmaceutical companies in Serbia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze